

combination therapy (with a 54% reduction in the estimated risk of disease progression). Grade 3–4 treatment-related sensory neuropathy (21% vs 0%), fatigue (9% vs 3%), and neutropenia (68% vs 11%) were more frequent with combination therapy in the total population.

Conclusion: Ixabepilone plus capecitabine is superior to capecitabine alone in MBC patients rapidly progressing after anthracycline/taxane treatment. This benefit is also confirmed in first-line patients who progress after adjuvant anthracycline/taxane therapy.

2102

ORAL

New insights in epirubicin (E) cardiac toxicity. An analysis of 1097 patients (pts) treated for metastatic breast cancer (MBC)

M. Ryberg¹, D.N. Nielsen², G. Cortese³, P.K. Andersen⁴, T. Skovsgaard⁵.

¹Herlev Hospital University of Copenhagen, oncology, Herlev, Denmark;

²Herlev hospital University of Copenhagen, oncology, Herlev, Denmark;

³University of Padova, Department of Statistical Sciences, Padova, Italy;

⁴Institute of Public Health's University of Copenhagen, Department of Biostatistics, Copenhagen, Denmark; ⁵Herlev Hospital University of Copenhagen, Department of Oncology, Herlev, Denmark

Background: The object of the study was to conduct an analysis and assess a recommended cumulative dose of E corresponding to a 5% risk for cardiotoxicity taking into account: dose administrations, concurrent risk of dying of MBC and possible predictors of cardiotoxicity. **Methods:** Data from 1097 consecutive anthracycline naive pts was retrieved retrospectively. Pts developing cardiac heart failure according to New York Heart Association (NYHA) Class ≥ II were recorded as having E cardiotoxicity. **Statistics:** two extended Cox multivariate analysis (events: cardiotoxicity and mortality of MBC) followed by competing risk analysis.

Results: 125 pts (11.4%) developed cardiotoxicity. Predictors for increasing the cardiotoxicity hazard ratio (HR) were: 1. cumulative dose of E: as the rate increased with 37% per every 100 mg/m² E, when given as first line treatment for advanced disease, 2. increasing age as the rate increased with 28.7% per additional 10 year, 3. x-ray including the heart (HR = 2.08), 4. tamoxifen for relapse (HR = 1.87), 5. predisposition to cardiac disease (HR = 3.01). Mortality rate for MBC: the survival was significant lower in pts with increasing tumour burden, poorer performance status, previous adjuvant CMF, and with increasing age. The HR for mortality was significantly increased by increased duration of treatment with E and was highest in the first three months than later on. The risk of cardiotoxicity increased mostly during the first 8 months after cessation of E nearly becoming constant later on. The cumulative dose of E corresponding to a 5% cardiotoxicity risk was found to be both significantly lower than previously assumed (900 mg/m²) and depend on predictors for mortality and cardiotoxicity. Thus, for pts with no predictors at age 40 the level of 5% risk was 806 mg/m², at age 50: 739 mg/m², at age 60: 673 mg/m², and at age 70: 609 mg/m².

Conclusion: The risk of cardiotoxicity of E was more pronounced than expected and occurred on a much lower cumulative dose of E. Increasing age, x-ray, tamoxifen and pre-disposition to cardiac disease contributed significantly to this.

2103

ORAL

A randomized, double-blind phase 2 study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)

S. Chan¹, A. Stopeck², A.A. Joy³, S. Verma⁴, A. Lluch⁵, F.K. Liau⁶, S. Kim⁶, P.W. Bycott⁶, D. Soulieres⁷, H. Rugo⁸. ¹Nottingham City Hospital, Clinical Oncology, Nottingham, United Kingdom; ²Arizona Cancer Center, Medicine, Tucson, USA; ³Cross Center Institute, Medical Oncology, Edmonton, Canada; ⁴Ottawa Regional Cancer Center, Medical Oncology, Ottawa, Canada; ⁵Hospital Clínico Universitario de Valencia, Servicio de Oncología, Valencia, Spain; ⁶Pfizer Inc., Global Research & Development, San Diego, USA; ⁷Hôpital Notre-dame du Center Hospitalier, Oncology, Montreal, Canada; ⁸University of California, Medicine, San Francisco, USA

Background: Single-agent DOC is commonly used to treat MBC. AG is a potent TKI of VEGFR 1, 2 & 3. A phase 1 lead-in study identified 80 mg/m² q3wks of DOC in combination with 5 mg BID of AG as the recommended phase 2 dose. The primary objective was to determine whether the time to progression (TTP) of the AG+DOC arm is superior to that of the DOC+PL arm.

Methods: Pts with no prior chemotherapy for MBC and ≥12 mos from adjuvant chemotherapy (aCT), measurable disease, ECOG performance status (PS) of 0–2, and no uncontrolled brain metastases were randomly

assigned (2:1) to receive treatment with either DOC+AG or DOC+PL, without prophylactic growth factor in cycle 1. Tumor measurements were performed q9wks. Pts were stratified according to estrogen receptor (ER) status, prior aCT and PS (0/1 or 2).

Results: A total of 168 pts were randomized. 92 pts had received prior aCT, 27 of whom received a prior taxane. Treatment arms were well balanced for prior adjuvant and taxane therapy. A median of 7 cycles of AG+DOC (range: 1–18) and 7 cycles of DOC+PL (range: 1–23) were administered. The most common non-hematologic all-grade adverse events observed in the AG+DOC arm included diarrhea (60%), nausea (53%), alopecia (51%), fatigue (49%), stomatitis (44%), and vomiting (40%). Grade 3/4 hematologic toxicities were similar in both arms. The median TTP (by RECIST) was 8.2 mo with AG+DOC and 7.0 mo with DOC+PL, with a hazard ratio (AG:PL) of 0.73 (prespecified, one-sided $p = 0.052$). The overall response rate (ORR) was 40% in the AG+DOC arm and 23% in the DOC+PL arm ($p = 0.038$), with a duration of response of 6.9 and 5.3 mo respectively. In a hypothesis-generating subgroup analysis, the median TTP in patients receiving prior aCT was 9.0 mo with AG+DOC and 6.3 mo with DOC+PL, with a hazard ratio of 0.54 ($p = 0.012$). Within this stratum, ORR was 45% in the AG+DOC arm and 13% in the DOC+PL arm ($p = 0.003$).

Conclusions: The anti-angiogenic TKI AG combined with DOC (80 mg/m² q3wks) as first-line therapy for MBC has an acceptable safety profile and promising anti-tumor activity.

Poster presentations (Wed, 26 Sep, 14:00–17:00)

Breast cancer – advanced disease

2104

POSTER

Serum Levels of N-telopeptide (sNTX) and bone-specific alkaline phosphatase (BAP) in oncology patients (pts) who developed osteonecrosis of the jaw (ONJ) during therapy with intravenous bisphosphonates (IB)

M. Fornier¹, A. Farooki², C. Estilo³, A. Conlin¹, S. Patil⁴, M. Fleisher⁵, J. Huryn¹, C. Hudis¹. ¹Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, New York NY, USA; ²Memorial Sloan-Kettering Cancer Center, Endocrinology Service, New York NY, USA; ³Memorial Sloan-Kettering Cancer Center, Dental Service, New York NY, USA; ⁴Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York NY, USA; ⁵Memorial Sloan-Kettering Cancer Center, Department of Clinical Laboratories, New York NY, USA

Background: IB including pamidronate and zoledronic acid are routinely utilized in the treatment of pts with metastatic breast, lung and prostate carcinoma to bones, and multiple myeloma, since a decreased incidence of skeletal complications was reported with their use. (Hortobagyi et al, N Engl J Med 1996) ONJ is a serious complication of long-term therapy with IB, and its incidence is as high as 7.7% in pts on chronic IB therapy. (Bamias et al, J Clin Oncol 2005) sNTX and BAP are biochemical markers of bone turn-over and can be suppressed by IB. A major hypothesis for the etiology of ONJ is over-suppression of bone turn-over. (Woo et al, Ann Internal Med 2006) To test this hypothesis we tested sNTX and BAP before and after the diagnosis of ONJ.

Materials and Methods: We identified a database of 75 oncology pts who developed ONJ between 2003–2006 and were seen by our Dentistry Service. 28 eligible pts had stored serum samples at 3 time-points: one year prior to ONJ diagnosis, 6 months prior, and proximate to the time of ONJ diagnosis.

Results: Of 28 pts: 75% were female; median age was 60 (range 43–81); primary diagnosis included metastatic breast carcinoma 68%, metastatic prostate carcinoma 21%, and multiple myeloma 11%. Median months of IB prior to diagnosis of ONJ was 33 (range 3.4–118.7). Laboratory normal ranges for sNTX and BAP are 5.5–19.5 nM BCE, and 14.2–42.7 Units/L, respectively. The median level of sNTX and BAP proximate to the time of ONJ diagnosis in our cohort was 11.4 nM BCE (range 7.6–23.2) and 21 Units/L (range 8–160), respectively. 96% and 86% of patients had normal levels of sNTX and BAP, respectively, at the time of ONJ diagnosis. There was no evidence of a downward trend of sNTX and BAP serum levels approaching (one year and 6 months prior) diagnosis of ONJ.

Conclusions: In this single-institution cohort of pts who developed ONJ on IB:

1. There was no evidence of very low absolute serum levels of sNTX and BAP and
2. There was no evidence of a downward trend in sNTX and BAP serum levels over the year prior to diagnosis.

With the limitations of small sample size and lack of control for diurnal variations of sNTX, our retrospective analysis does not support the hypothesis that, in the setting of IB use, systemic over-suppression of bone turn-over as revealed by biochemical markers, is associated with development of ONJ. Prospective trials to identify pts' characteristics and markers predictive for ONJ are needed.

2105

POSTER

An accelerated loading regimen for trastuzumab leads to early higher than steady-state serum concentrations

B. Leyland-Jones¹, R. Colomer², M. Trudeau³, A. Wardley⁴, J. Latreille⁵, D. Cameron⁶, R. Cubedo⁷, N. Al-Sakaff⁸, J.E. Charoin⁹, J. Cortés⁹.
¹McGill University Hospital, Montreal, Québec, Canada; ²Hospital Universitari Doctor Josep Trueta, Oncology, Girona, Spain; ³Toronto Sunnybrook Regional Cancer Centre, Oncology, Toronto, Canada; ⁴Christie Hospital NHS Trust, Oncology, Manchester, United Kingdom; ⁵Hôpital Charles LeMoine, Taschereau, Québec, Canada; ⁶Western General Hospital, Oncology, Edinburgh, United Kingdom; ⁷Hospital Puerta de Hierro, Oncology, Madrid, Spain; ⁸F. Hoffmann-La Roche, Oncology, Basel, Switzerland; ⁹Vall d'Hebron University Hospital, Oncology, Barcelona, Spain

Background: Serum concentrations of trastuzumab (Herceptin®; H) normally take 18–24 weeks to reach steady-state levels with currently used regimens (qw or q3w). Achieving higher than steady-state H concentrations earlier in the course of treatment could result in earlier benefits including tumour shrinkage in patients (pts) with HER2-positive metastatic breast cancer (MBC). To investigate this further, we examined the pharmacokinetics (PK) and tolerability of a novel higher-dose loading regimen of H, based on PK simulation.

Methods: Pts with HER2-positive MBC were given a 6 mg/kg iv loading dose of H on days 1, 8 and 15, followed by 6 mg/kg q3w from day 22. Blood samples for PK analysis were collected at various time points within the first 4 cycles (12 weeks). All PK data were analysed by non-linear mixed-effect modelling (population PK). Safety and efficacy analyses were also performed.

Results: PK was analysed in 71/72 enrolled pts (median age 59 years; median weight 69.75 kg; 56 pts had received previous chemotherapy [CT]: 46 for early breast cancer, 10 for MBC, 16 pts had no prior CT). In cycle 1, predicted exposure levels were already higher than previously reported steady-state exposure levels with conventional dosing regimens (Charoin et al 2004) (table).

PK parameter	Units	Median level		
		Cycle 1	Cycle 5	Conventional regimen
AUC _{0-3wks}	mg-day/L	2712.9	1996.3	1793
C _{max}	mg/L	235.8	203.4	189
C _{min}	mg/L	119.8	54.9	47.3

The regimen was well tolerated, with 3 pts (4.2%) withdrawing due to adverse events. One pt experienced a drop in left ventricular ejection fraction to <40% and no pts experienced symptomatic heart failure. The response rate (RR) was 26.8% (11/41 evaluable pts), with a median time to progression (TTP) of 7.7 months.

Conclusions: This regimen achieved higher than steady-state serum concentrations of H during the first q3w treatment cycle without diminished tolerability. RR was higher and TTP was longer than previously seen with monotherapy. Treatment with this intensive loading dose regimen of H has the potential to improve efficacy and maximise synergies when combined with CT.

References

Charoin JE, et al. (2004) Population pharmacokinetic analysis of trastuzumab (Herceptin) following long-term administration using different regimens. Poster 33 presented at the Population Approach Group in Europe 13th Meeting, Uppsala, Sweden, 17–18 June, 2004. Available at: <http://www.page-meeting.org>.

2106

POSTER

Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer

W.J. Gradishar¹, D. Krasnojon², S. Cheporov³, A. Makhson⁴, M. Georgy⁵, A. Clawson⁶, M.J. Hawkins⁷. ¹Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology Department of Medicine, Chicago Illinois, USA; ²Leningrad Regional Oncology Center, St. Petersburg, Russian Federation; ³Yaroslavl Regional Oncology Center, Yaroslavl, Russian Federation; ⁴City Oncology Hospital, Moscow, Russian Federation; ⁵St. Petersburg Oncology Center, St. Petersburg, Russian Federation; ⁶Abraxis BioScience Inc., Biostatistics, Durham North Carolina, USA; ⁷Abraxis BioScience Inc., Los Angeles California, USA

Background: 130-nanometer albumin-bound- (nab-) paclitaxel (Abraxane®) combines paclitaxel with albumin without solvents or altering either component. A cross analysis of 2 clinical trials comparing solvent-based (SB) paclitaxel 175 mg/m² every 3 weeks (q3w) to nab-paclitaxel (Gradishar et al, JCO, 2005) and SB docetaxel (Jones et al, JCO, 2005) suggested comparable antitumor activity between nab-paclitaxel and SB docetaxel and better tolerability with nab-paclitaxel in patients (pts) with metastatic breast cancer (MBC). The aim of this study was to compare the toxicity and antitumor activity of 3 regimens of nab-paclitaxel (q3w and 2 weekly) with each other and that of SB docetaxel in MBC.

Methods: In this open-label study, first-line pts with MBC were randomly assigned to nab-paclitaxel 300 mg/m² q3w (A); nab-paclitaxel 100 mg/m² (B) or 150 mg/m² (C) days 1, 8, and 15, q28 days (q 3/4 w); or SB docetaxel 100 mg/m² q3w (D). The primary endpoints were overall response rate (complete response + partial response), evaluated every 8 weeks and toxicity. Progression-free survival (PFS) was also determined.

Results: 302 pts [median age, 54 years; 99% Caucasian; 75% post-menopausal; Eastern Collaborative Oncology Group (ECOG) Performance Score (PS) ≤2 (94% ≤1)] either had at least 2 response assessments (94%) or had discontinued due to progressive disease (PD; 6%). The efficacy results at the time of a planned interim analysis conducted in November, 2006 are shown in the Table. Neutropenia (N) was greater with D than with A, B, or C (p < .001). Grade 4 N was: (A) 4%, (B) 3%, (C) 7%, and (D) 74%. Febrile neutropenia (FN) was: (A) 1%, (B) 1%, (C) 1%, and (D) 7%. Gr 3 peripheral neuropathy was: (A) 14%, (B) 7%, (C) 12%, and (D) 5%.

Efficacy results^a

	(A) nab-Pac 300 mg/m ² q3w (n = 76)	(B) nab-Pac 100 mg/m ² q3/4w (n = 76)	(C) nab-Pac 150 mg/m ² q3/4w (n = 74)	(D) Solvent-based Doc 100 mg/m ² q3w (n = 74)
Overall response rate (CR + PR)	25 (33%)	44 (58%)	46 (62%)	27 (36%)
P-value vs. D ^b	Not calculated	0.004	0.016	–
P-value vs. B ^b	<0.001	–	0.424	–
P-value vs. C ^b	<0.001	–	–	–
Number of pts with PFS event	23 (30%)	25 (33%)	19 (26%)	33 (45%)
Median PFS (months)	>10.6	9.3	9.2	7.3
95% CI	7.3–>10.6	7.1–>10.6	8.1–>10.8	5.6–8.4

^aPac, paclitaxel; Doc, docetaxel; CR, complete response; PR, partial response.

^bP-value based on a Cochran-Mantel-Haenszel test stratified by study site.

Conclusions: The response rates of q3w nab-paclitaxel and solvent-based docetaxel were comparable. Q 3/4 w nab-paclitaxel resulted in higher response rates than SB docetaxel. Grade 4 N and FN were less frequent with nab-paclitaxel as compared with solvent-based docetaxel. At the time of this interim analysis, all 3 nab-paclitaxel regimens have a longer PFS than SB docetaxel. Current data will be presented for toxicity and from a radiological review of response data and PFS. As of 10 April 2007, 146 (49%) of PFS events had occurred, and it is projected that sufficient events (≥80%) for a final PFS analysis will occur by August, 2007.